Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
January 05, 2023 09:19 ET
|
Revive Therapeutics Ltd.
TORONTO, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
December 22, 2022 14:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Ltd. Expands Life Offering to Quebec
December 15, 2022 07:29 ET
|
Revive Therapeutics Ltd.
TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) announces that it is expanding its previously announced private placement...
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
November 30, 2022 17:43 ET
|
Revive Therapeutics Ltd.
TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) is pleased to announce that it is arranging a private placement of a minimum...
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
November 24, 2022 09:18 ET
|
Revive Therapeutics Ltd.
TORONTO, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
November 22, 2022 09:20 ET
|
Revive Therapeutics Ltd.
TORONTO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
October 14, 2022 13:34 ET
|
Revive Therapeutics Ltd.
TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
October 06, 2022 10:18 ET
|
Revive Therapeutics Ltd.
TORONTO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
September 28, 2022 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program
September 16, 2022 06:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...